| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Experimental Therapeutics and Pharmaceutical Development Center, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77054;
2 Institute for Integrative Cancer Care, Evanston, IL 60201
The class of steroid-like compounds designated cardiac glycosides includes well-known drugs such as digoxin, digitoxin, and ouabain. Their continued efficacy in treatment of congestive heart failure and as anti-arrhythmic agents is well appreciated. Less well known, however, is the emerging role of this category of compounds in the prevention and/or treatment of proliferative diseases such as cancer. New findings within the past five years have revealed these compounds to be involved in complex cell-signal transduction mechanisms, resulting in selective control of human tumor but not normal cellular proliferation. As such, they represent a promising form of targeted cancer chemotherapy. New clinical studies of their anticancer potential as single or adjuvant treatments may provide insight into these potentially valuable therapeutic options. This review focuses on recent findings on cellular pharmacology of cardiac glycosides as they relate to treatment of human cancer and attempts to explain why these agents have been overlooked in the past.
This article has been cited by other articles:
|
|
 |
|
  Z. Wang, M. Zheng, Z. Li, R. Li, L. Jia, X. Xiong, N. Southall, S. Wang, M. Xia, C. P. Austin, et al. Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition Cancer Res., August 15, 2009; 69(16): 6556 - 6564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Yang, D. G. Menter, C. Cartwright, D. Chan, S. Dixon, M. Suraokar, G. Mendoza, N. Llansa, and R. A. Newman Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase {alpha} subunits as drug targets Mol. Cancer Ther., August 1, 2009; 8(8): 2319 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antczak, C. Kloepping, C. Radu, T. Genski, L. Muller-Kuhrt, K. Siems, E. de Stanchina, D. H. Abramson, and H. Djaballah Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3065 - 3073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tian, X. Li, M. Liang, L. Liu, J. X. Xie, Q. Ye, P. Kometiani, M. Tillekeratne, R. Jin, and Z. Xie Changes in Sodium Pump Expression Dictate the Effects of Ouabain on Cell Growth J. Biol. Chem., May 29, 2009; 284(22): 14921 - 14929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, D. Z. Qian, Y. S. Tan, K. Lee, P. Gao, Y. R. Ren, S. Rey, H. Hammers, D. Chang, R. Pili, et al. Inaugural Article: Digoxin and other cardiac glycosides inhibit HIF-1{alpha} synthesis and block tumor growth PNAS, December 16, 2008; 105(50): 19579 - 19586. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |
